FRI0137 Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ)

Abstract

BackgroundThe increased incidence of MACE in RA cannot be explained by traditional CV risk factors alone.1ObjectivesTo examine associations of lipids, inflammation and RA disease activity with risk for MACE in...